Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | DGKA | P23743 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | WRN | Q14191 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6792231 | 0.86 | NAAA (0.50) | NAAAHTTDGKAGAAALDH1A1 | |
| SCHEMBL29176453 | 0.83 | NAAA (0.57) | NAAAHTTDGKAGAAALDH1A1 | |
| SCHEMBL27631198 | 0.82 | CYP1A2 (0.47) | NAAADGKAGAAALDH1A1CYP1A2 | |
| SCHEMBL2600809 | 0.81 | NAAA (0.73) | NAAAHTTDGKAGAAALDH1A1 | |
| SCHEMBL50185 | 0.81 | NAAA (0.81) | NAAAHTTDGKAGAAALDH1A1 | |
| SCHEMBL18823278 | 0.81 | HTR2C (0.41) | NAAADGKAALDH1A1RAD52NPSR1 | |
| SCHEMBL27343802 | 0.81 | NAAA (0.55) | NAAAHTTDGKAGAAALDH1A1 | |
| SCHEMBL16213963 | 0.80 | NAAA (0.50) | NAAAHTTDGKAGAAALDH1A1 | |
| SCHEMBL249417 | 0.79 | ALDH1A1 (0.38) | NAAAHTTGAAALDH1A1ATM | |
| SCHEMBL14081984 | 0.79 | DGKA (0.69) | NAAADGKAALDH1A1RAD52NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786605-B2 | Site specific antibody-drug conjugates with peptide-containing linkers | MERSANA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | ASANA BIOSCIENCES, LLC | 2023-06-15 | — | — | US | disclosed |
| US-20180154018-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180140716-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2018-05-24 | — | — | US | disclosed |
| US-9943609-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9872918-B2 | Hydroxyl-polymer-drug-protein conjugates | MERSANA THERAPEUTICS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9849191-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-9808528-B2 | Protein-polymer-drug conjugates and methods of using same | MERSANA THERAPEUTICS, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9770519-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20150064130-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-03-05 | — | — | US | disclosed |
| US-20150044160-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-02-12 | — | — | US | disclosed |
| US-8821850-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8815226-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8808679-B2 | Auristatin compounds and conjugates thereof | MERSANA THERAPEUTICS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140134127-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140017265-A1 | Terminally Modified Polymers and Conjugates Thereof | MERSANA THERAPEUTICS, INC. | 2014-01-16 | — | — | US | disclosed |
| US-20130309192-A1 | Auristatin Compounds and Conjugates Thereof | MERSANA THERAPEUTICS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130101546-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20120321583-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2012-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150044160-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | NAAA 3420/4885HTT 3407/4885DGKA 3448/4885 |
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | NAAA 3420/4885HTT 3407/4885DGKA 3448/4885 |
| US-20140134127-A1 | Protein-Polymer-Drug Conjugates | PBRM1, CLTB, BRAP | NAAA 3420/4885HTT 3407/4885DGKA 3448/4885 |
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | NAAA 3020/4885HTT 4197/4885DGKA 4406/4885 |
| US-20180140716-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | NAAA 3020/4885HTT 4197/4885DGKA 4406/4885 |
| US-20140017265-A1 | Terminally Modified Polymers and Conjugates Thereof | MALT1, ALG1, PRMT3 | NAAA 4202/4885HTT 1332/4885DGKA 4447/4885 |
| US-11786605-B2 | Site specific antibody-drug conjugates with peptide-containing linkers | CD2BP2, DNPEP, LNPEP | NAAA 2915/4885HTT 4091/4885DGKA 2342/4885 |
| US-20120321583-A1 | Protein-Polymer-Drug Conjugates | PBRM1, CLTB, BRAP | NAAA 3420/4885HTT 3407/4885DGKA 3448/4885 |
| US-20150064130-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, PEBP1, STAMBP | NAAA 2335/4885HTT 3634/4885DGKA 4175/4885 |
| US-20180154018-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | CD2BP2, DNPEP, LNPEP | NAAA 2654/4885HTT 3239/4885DGKA 2497/4885 |
| US-20130101546-A1 | Protein-Polymer-Drug Conjugates | PBRM1, CLTB, BRAP | NAAA 3360/4885HTT 3154/4885DGKA 3425/4885 |
| US-20130309192-A1 | Auristatin Compounds and Conjugates Thereof | PBRM1, AURKB, PEBP1 | NAAA 1955/4885HTT 4019/4885DGKA 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.